Strategic asset sale AgBiome recently completed the sale of its platform assets, including a vast repository of strains and gene sequences, to Ginkgo Bioworks. This indicates a potential shift in strategic capabilities and a possible interest in partnerships or licensing of remaining technologies and pipeline assets.

Expansion to fungicides The introduction of Howler EVO in 2023 shows ongoing product development in fungicides, signaling opportunities to cross-sell or bundle with existing microbial products, and potential channel partnerships with crop protection distributors.

Strong funding With total funding of 253M and current revenue in the mid-range for biotech crops, there is capital availability for additional collaborations, joint ventures, or contract research with agribusiness partners seeking innovative biological solutions.

Strategic partnerships Past collaborations, such as the Gore partnership on microbial production, suggest appetite for co-development or manufacturing partnerships to scale production, improve formulations, or access new markets.

Market readiness AgBiome operates a commercial subsidiary with ready-to-sell crop protection products and a GENESIS discovery platform, implying sales opportunities with agricultural retailers, distributors, and growers seeking effective biological and trait-based solutions.